Research Library
TIRZ GLP-2 research
6 articles to explore, with links to 8 original sources.
About TIRZ GLP-2
TIRZ is the catalog name for tirzepatide, a peptide investigated at GIP and GLP-1 receptors.
Understand the science
How a pragmatic trial studies tirzepatide in everyday care
Tirzepatide is a GIP and GLP-1 receptor agonist peptide. The “GLP-2” in this catalog label does not identify a receptor it activates. In 2026, the SURMOUNT-REAL UK investigators published a plan to assess how offering tirzepatide would affect outcomes in a routine primary care setting.
2 sources (2022, 2026)
Explore study findings
What the lowest recorded weight adds to a three-year analysis
Tirzepatide acts at GIP and GLP-1 receptors. The “TIRZ GLP-2” catalog wording refers to tirzepatide rather than the GLP-2 receptor. A 2026 analysis explored how much weight participants regained from their lowest recorded weight while they remained in a long-term study.
2 sources (2022, 2026)
What researchers observed after tirzepatide withdrawal
Tirzepatide is a GIP and GLP-1 receptor agonist peptide. The “TIRZ GLP-2” label identifies the catalog entry. In a later analysis of SURMOUNT-4, researchers examined how weight regain after withdrawal related to changes in blood pressure, waist circumference and other measures.
2 sources (2022, 2025)
Check methods and identity
What the Japanese tirzepatide trial measured around the abdomen
Tirzepatide is a modified peptide that activates GIP and GLP-1 receptors. The “GLP-2” in this catalog label is an identifier and does not describe tirzepatide’s receptor targets.
1 source (2026)
How sleep and weight measurements related to blood pressure
Tirzepatide acts at GIP and GLP-1 receptors, regardless of the “GLP-2” wording used in the catalog. A 2026 analysis of the SURMOUNT-OSA trials examined how changes in sleep apnea measurements and weight were related to changes in cardiovascular risk markers.
2 sources (2024, 2026)
Interpret the evidence
Why an early weight response did not tell the whole story
Tirzepatide is a peptide that activates GIP and GLP-1 receptors. “TIRZ GLP-2” is the catalog’s wording for this molecule. A 2026 analysis asked how participants’ early weight changes related to their outcomes at a later visit.
2 sources (2022, 2026)
